The study focuses on Heart failure, a condition in which the heart cannot pump blood as well as it should, leading to fluid buildup and shortness of breath. Participants will receive the medication acetazolamide, sold under the code name DIAMOX, in addition to their usual heart medicines such as furosemide, a drug that helps the kidneys remove excess fluid. The purpose of the study is to determine whether adding this medication helps reduce fluid overload and improve symptoms compared with standard therapy alone.
During the trial, individuals will take the study drug for a short period while their weight is measured each day using a connected scale that sends data through remote monitoring to the study team. Researchers will look at how much weight is lost, changes in breathing difficulty, and a blood test called NtproBNP, which rises when the heart is under stress. The study runs for a few weeks, with follow‑up visits to check health status and any need for urgent care or hospital visits.
France 
